TITLE

CHELSEA THERAPEUTICS INITIATES CH-150 BIOEQUIVALENCE STUDY

PUB. DATE
August 2007
SOURCE
Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the CH-1504 bioequivalency study was initiated by the Chelsea Therapeutics International, Ltd. in Charlotte, North Carolina. The study was conducted at Swiss Pharma in Basel, Switzerland. It was noted that the preclinical and clinical data were expected to enable the company to initiate Phase II trials of CH-1504 in RA during the fourth quarter of 2007. Among the diseases that may benefit from the compound includes psoriasis, inflammatory bowel disease and cancer.
ACCESSION #
25887427

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;10/30/2008, Vol. 19 Issue 212, p6 

    This section offers news related to clinical trials. Dosing of ANA598 in patients chronically infected with hepatitis C virus has been started by Anadys Pharmaceuticals Inc. in a Phase Ib study. Enrollment has been completed in Chelsea Therapeutics International Limited's Phase II trial...

  • Clinic Roundup.  // BioWorld Today;1/24/2011, Vol. 22 Issue 15, p3 

    The article presents updates on clinical trials conducted by biotechnology companies. The data on the Phase II trial of telatinib in patients with metastatic stomach cancer supported the potent nature of the antiangiogenic agent developed by ACT Biotech Inc. Data from a safety extension study...

  • Saturable Active Tubular Reabsorption in the Renal Clearance of Mesalazine in Human Volunteers. Vree, T.B.; Dammers, E.; Exler, P.S.; Sörgel, F.; Maes, R.A.A. // Clinical Drug Investigation;2000, Vol. 20 Issue 1, p35 

    Objective: To identify the reasons for the large variation in renal clearance of mesalazine. Design: Data were obtained from a randomised crossover bioequivalence study in 18 healthy volunteers. Methods: Participants received a single 1000mg oral dose of each of two different formulations of...

  • Chelsea's Droxidopa Flameout: Hope Alive for Second Phase III. Hollingsworth, Catherine // BioWorld Today;9/25/2009, Vol. 20 Issue 185, p1 

    The article reports on a decline in the value of shares owned by Chelsea Therapeutics International. Shares of the company declined by 61% after news that its most advanced production, droxidopa, for low blood pressure failed in a Phase II study. The drug is being tested in patients with...

  • Chelsea completes enrollment for Phase II hypotension trial.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p5 

    The article reports on the patient enrollment completed by Chelsea Therapeutics International Ltd. in its Phase II trial of Droxidopa in patients with intradialytic hypotension in the U.S. The trial is a multi-center, double-blind, placebo controlled study that compared 400 milligrams (mg) and...

  • Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach. GROSSI, FRANCESCO; AITA, MARIANNA; DEFFERRARI, CARLOTTA; ROSETTI, FRANCESCO; BRIANTI, ANNALISA; FASOLA, GIANPIERO; VINANTE, ORAZIO; PRONZATO, PAOLO; PAPPAGALLO, GIOVANNI // Oncologist;May2009, Vol. 14 Issue 5, p497 

    Background. The therapeutic equivalence of different third-generation agents in the first-line treatment of advanced non-small cell lung cancer (NSCLC) has long been accepted, although recent studies seem to suggest some superiority of gemcitabine- or docetaxel-containing regimens over other...

  • FDA Update.  // Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p11 

    The article offers updates relative to the U.S. Food and Drug Administration. FDA has engaged a series of studies designed to test varied ways of demonstrating the benefits and risks in direct-to-consumer (DTC) promotion of prescription drugs. FDA has approved Centocor Ortho Biotech Inc.'s...

  • Inflammatory bowel disease III.  // Gut;Jul2012 Supplement, Vol. 61, pA389 

    The article presents abstracts on medical topics of Great Britain which include the clinical trials on inflammatory bowel disease, efficacy of the faecal lactoferrin on the inflammatory bowel disease and the results of cytomegalovirus colitis on patients.

  • Colorectal Cancer in IBD Patients. Stormont, James M; Shah, Ashok N; Sharma, Anil K; Saubermann, Lawrence J; Farmer, Richard G // American Journal of Gastroenterology;Sep2013, Vol. 108 Issue 9, p1535 

    A letter to the editor is presented in response to the article regarding colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics